GoodRx (NASDAQ:GDRX) Receives “Neutral” Rating from JPMorgan Chase & Co.

GoodRx (NASDAQ:GDRX)‘s stock had its “neutral” rating reaffirmed by stock analysts at JPMorgan Chase & Co. in a research note issued on Friday,Benzinga reports.

Several other research analysts have also issued reports on GDRX. Barclays assumed coverage on GoodRx in a research report on Monday, December 8th. They issued an “underweight” rating and a $3.00 target price for the company. Morgan Stanley decreased their price objective on GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. Leerink Partners reissued an “outperform” rating and set a $3.00 price objective on shares of GoodRx in a research report on Thursday. Bank of America reaffirmed a “reduce” rating on shares of GoodRx in a research report on Monday, January 5th. Finally, TD Cowen decreased their price target on shares of GoodRx from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, November 10th. Five research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, GoodRx presently has a consensus rating of “Hold” and a consensus target price of $4.60.

GoodRx Stock Down 18.8%

Shares of NASDAQ GDRX opened at $1.99 on Friday. The firm has a fifty day simple moving average of $2.52 and a two-hundred day simple moving average of $3.27. GoodRx has a 12 month low of $1.92 and a 12 month high of $5.81. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $675.47 million, a PE ratio of 22.11, a price-to-earnings-growth ratio of 0.93 and a beta of 1.50.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Wednesday, February 25th. The company reported $0.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.09. GoodRx had a net margin of 3.82% and a return on equity of 9.25%. The firm had revenue of $194.79 million for the quarter, compared to analyst estimates of $193.27 million. During the same quarter in the previous year, the firm posted $0.09 EPS. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. Equities analysts expect that GoodRx will post 0.13 earnings per share for the current year.

Institutional Trading of GoodRx

Institutional investors have recently made changes to their positions in the stock. Meridian Wealth Management LLC purchased a new stake in GoodRx in the fourth quarter worth approximately $29,000. Quarry LP purchased a new position in shares of GoodRx in the 3rd quarter worth $33,000. MML Investors Services LLC bought a new stake in shares of GoodRx in the fourth quarter worth $36,000. DRW Securities LLC purchased a new stake in GoodRx during the fourth quarter valued at $40,000. Finally, Boothbay Fund Management LLC bought a new position in GoodRx in the third quarter valued at about $43,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.